Rosen law firm urges regeneron pharmaceuticals, inc. (nasdaq: regn) stockholders to contact the firm for information about their rights

New york--(business wire)--rosen law firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of regeneron pharmaceuticals, inc. (nasdaq: regn) between november 2, 2023 and october 30, 2024. regeneron describes itself as a “biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.” for more information, submit a form, email.
REGN Ratings Summary
REGN Quant Ranking